Professor Sallie Pearson

Research Interests:

Sallie is a pharmacoepidemiologist and health service researcher. She has two decades' experience in quality use of medicines research. Her specific research interests include post-market surveillance of medicines, evaluating the impact of pharmaceutical policy interventions and prescriber behaviour change. Sallie completed her doctoral training at the University of Newcastle, Australia (1998) and her Postdoctoral Fellowship in Pharmaceutical Policy at Harvard Medical School (2000-2001). Sallie established the Medicines Policy Research Unit in 2005 and joined the Centre for Big Data Research in Health (CBDRH), Faculty of Medicine, University of NSW in 2016. Sallie is currently the Director of the Centre of Research Excellence in Medicines Intelligence and Head of the Medicines Policy Research Unit, CBDRH. She holds an Honorary Professorial appointment at the Menzies Centre for Health Policy, University of Sydney. Sallie has been actively engaged in a range of committees and advisory groups including the NSW Population and Health Services Research Ethics Committee (Deputy Chair: 2006-2011; Chair 2012-2017) and the Drug Utilisation Sub-Committee of the Pharmaceutical Benefits Advisory Committee (2011-), Australian Commission for Safety and Quality and Health Care Medication Oversight Committee (2018-), the National Data Advisory Council (2019-) and the National COVID-19 Clinical Evidence Taskforce (Co-Chair Observational Data Working Group, 2020-). 

Broad Research Areas:
Population Health, Health Services Research, Cancer, Epidemiology, Health Policy

Qualifications:
PhD

Society Memberships & Professional Activities:
Member, Health Service Research Association of Australia and New Zealand; Member, International Society of Pharmacoepidemiology; Member, Harvard Club of Australia; Chair, NSW Population & Health Services Research Ethics Committee; Member, Drug Utilisation Sub-Committee of the Pharmaceutical Benefits Advisory Committee.

Specific Research Keywords:
Pharmacoepidemiology, Cancer, Health Services Research, Rational Drug Use, Program Evaluation